by TOKYO — Analysts are break up on the outlook for Japanese drugmaker Eisai’s new Alzheimer’s therapy, with questions remaining over what number of hospitals can have the diagnostic capabilities wanted to manage it.
Lecanemab, developed with American associate Biogen, obtained fast-track approval from the U.S. Food and Drug Administration on Jan. 7. Eisai CEO Haruo Naito estimates that 100,000 American sufferers shall be eligible for the drug in three years.
